Medical management of recurrent endometrioma with long-term norethindrone acetate

Ozgul Muneyyirci-Delale1,2, Jenny Anopa1, Cassandra Charles1, Deepali Mathur1, Rudolph Parris1, Jed B Cutler2, Ghadir Salame1,2, Ovadia Abulafia1,21Department of Obstetrics and Gynecology, SUNY Downstate Medical Center, New York, NY, USA; 2Department of Obstetrics and Gynecology, Kings County Hospit...

Full description

Bibliographic Details
Main Authors: Muneyyirci-Delale O, Anopa J, Charles C, Mathur D, Parris R, Cutler JB, Salame G, Abulafia O
Format: Article
Language:English
Published: Dove Medical Press 2012-03-01
Series:International Journal of Women's Health
Online Access:http://www.dovepress.com/medical-management-of-recurrent-endometrioma-with-long-term-norethindr-a9605
id doaj-53e0fe612f184a4d8fd777b686f11822
record_format Article
spelling doaj-53e0fe612f184a4d8fd777b686f118222020-11-24T22:23:04ZengDove Medical PressInternational Journal of Women's Health1179-14112012-03-012012default149154Medical management of recurrent endometrioma with long-term norethindrone acetateMuneyyirci-Delale OAnopa JCharles CMathur DParris RCutler JBSalame GAbulafia OOzgul Muneyyirci-Delale1,2, Jenny Anopa1, Cassandra Charles1, Deepali Mathur1, Rudolph Parris1, Jed B Cutler2, Ghadir Salame1,2, Ovadia Abulafia1,21Department of Obstetrics and Gynecology, SUNY Downstate Medical Center, New York, NY, USA; 2Department of Obstetrics and Gynecology, Kings County Hospital Center, New York, NY, USAPurpose: Evaluate the efficacy of norethindrone acetate in the resolution of symptoms and regression of recurrent endometrioma.Patients and methods: Retrospective chart review at SUNY Downstate Medical Center of patients with a history of surgical excision of endometrioma (with histological confirmation) and recurrent endometrioma (demonstrated by strict sonographic criterion of endometrioma) who were willing to undergo follow-up. Patients were prescribed norethindrone acetate to be taken daily with follow-up sonograms until cysts regressed. Statistical analysis included Student's t-test and a simple linear regression model to assess cyst regression over time during treatment.Results: Degree of pain was significantly lower on treatment when compared to baseline (P < 0.00001). Cyst size was significantly smaller in as little as 3 months (P < 0.0001). Average rate of regression with continuous treatment was 0.025 ± 0.015 cm/day. Total mean ± standard deviation regression time is 10.28 ± 8.25 months.Conclusion: Norethindrone acetate was effective in eradicating symptoms and producing complete regression of recurrent endometriomas. It should be considered for patients who are likely to adhere to a prolonged treatment regimen and comply with recommendations for surveillance with serial sonograms.Keywords: endometriosis, regression, dysmenorrhea, medical therapyhttp://www.dovepress.com/medical-management-of-recurrent-endometrioma-with-long-term-norethindr-a9605
collection DOAJ
language English
format Article
sources DOAJ
author Muneyyirci-Delale O
Anopa J
Charles C
Mathur D
Parris R
Cutler JB
Salame G
Abulafia O
spellingShingle Muneyyirci-Delale O
Anopa J
Charles C
Mathur D
Parris R
Cutler JB
Salame G
Abulafia O
Medical management of recurrent endometrioma with long-term norethindrone acetate
International Journal of Women's Health
author_facet Muneyyirci-Delale O
Anopa J
Charles C
Mathur D
Parris R
Cutler JB
Salame G
Abulafia O
author_sort Muneyyirci-Delale O
title Medical management of recurrent endometrioma with long-term norethindrone acetate
title_short Medical management of recurrent endometrioma with long-term norethindrone acetate
title_full Medical management of recurrent endometrioma with long-term norethindrone acetate
title_fullStr Medical management of recurrent endometrioma with long-term norethindrone acetate
title_full_unstemmed Medical management of recurrent endometrioma with long-term norethindrone acetate
title_sort medical management of recurrent endometrioma with long-term norethindrone acetate
publisher Dove Medical Press
series International Journal of Women's Health
issn 1179-1411
publishDate 2012-03-01
description Ozgul Muneyyirci-Delale1,2, Jenny Anopa1, Cassandra Charles1, Deepali Mathur1, Rudolph Parris1, Jed B Cutler2, Ghadir Salame1,2, Ovadia Abulafia1,21Department of Obstetrics and Gynecology, SUNY Downstate Medical Center, New York, NY, USA; 2Department of Obstetrics and Gynecology, Kings County Hospital Center, New York, NY, USAPurpose: Evaluate the efficacy of norethindrone acetate in the resolution of symptoms and regression of recurrent endometrioma.Patients and methods: Retrospective chart review at SUNY Downstate Medical Center of patients with a history of surgical excision of endometrioma (with histological confirmation) and recurrent endometrioma (demonstrated by strict sonographic criterion of endometrioma) who were willing to undergo follow-up. Patients were prescribed norethindrone acetate to be taken daily with follow-up sonograms until cysts regressed. Statistical analysis included Student's t-test and a simple linear regression model to assess cyst regression over time during treatment.Results: Degree of pain was significantly lower on treatment when compared to baseline (P < 0.00001). Cyst size was significantly smaller in as little as 3 months (P < 0.0001). Average rate of regression with continuous treatment was 0.025 ± 0.015 cm/day. Total mean ± standard deviation regression time is 10.28 ± 8.25 months.Conclusion: Norethindrone acetate was effective in eradicating symptoms and producing complete regression of recurrent endometriomas. It should be considered for patients who are likely to adhere to a prolonged treatment regimen and comply with recommendations for surveillance with serial sonograms.Keywords: endometriosis, regression, dysmenorrhea, medical therapy
url http://www.dovepress.com/medical-management-of-recurrent-endometrioma-with-long-term-norethindr-a9605
work_keys_str_mv AT muneyyircidelaleo medicalmanagementofrecurrentendometriomawithlongtermnorethindroneacetate
AT anopaj medicalmanagementofrecurrentendometriomawithlongtermnorethindroneacetate
AT charlesc medicalmanagementofrecurrentendometriomawithlongtermnorethindroneacetate
AT mathurd medicalmanagementofrecurrentendometriomawithlongtermnorethindroneacetate
AT parrisr medicalmanagementofrecurrentendometriomawithlongtermnorethindroneacetate
AT cutlerjb medicalmanagementofrecurrentendometriomawithlongtermnorethindroneacetate
AT salameg medicalmanagementofrecurrentendometriomawithlongtermnorethindroneacetate
AT abulafiao medicalmanagementofrecurrentendometriomawithlongtermnorethindroneacetate
_version_ 1725766082790162432